石四药集团：取得吲哚布芬片药品生产注册批件

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has obtained the production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1]